Eptinezumab, a drug used for the long-term treatment of chronic migraine, has shown sustained efficacy in patients who did not respond to previous multidimensional preventive treatments, according to the results of the third phase of the DELIVER study.
Between weeks 61 and 72, it was reported that up to 70% of patients experienced a reduction in the number of monthly migraines by at least 50%.
More than 40% of participants reported a reduction rate of over 75%, according to graduate student Messoud Ashina.
Researchers say this treatment was associated with a decrease in the severity of headaches and the most bothersome symptoms, a decrease in the use of other medications, and improvements in quality of life and productivity.
Out of the more than 800 patients surveyed during the extension phase, only about 1.3% dropped out of the study due to side effects. Ashina stated that most of the side effects were related to disorders in the cranial region.
During the initial stages of the DELIVER trial, Eptinezumab had already demonstrated its ability to reduce the frequency of migraines. Even in the extension phase, patients who initially belonged to the placebo group and then switched to the active treatment group experienced rapid effects.
A notable finding is that lower doses of the antibody showed similar long-term effects as doses up to three times higher.
Ashina concluded that this is one of the second studies on the long-term efficacy of CGRP inhibitors.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”